March 15, 2021 5:25pm

Economic overheating and Fed tightening will be the newest normal

Pre-open indication results: 5 HITs and 2 MISS

Numbers based facts speak better then opinion as I see answers in numbers to speak truth over opinion!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence

The Dow closed UP +174.82 points (+0.53%); the S&P closed UP +25.60 points (+0.65%) while the Nasdaq closed UP +139.84 points (+1.05 %)

 

Henry’omics:

Optimism is growing about the economic reopening from the pandemic; but which plate will be served - inflation, corporate and personal higher tax rates, burgeoning bond yields and further bailouts of bad behaviors.

The small-cap benchmark Russell 2000 closed up 0.3% at a fresh record.

 

RegMed Investors’ (RMi) pre-open: “: sector hovers as markets expect discontent from Fed meeting What will “juice” this market?”  … https://www.regmedinvestors.com/articles/11814

 

Pre-open indication results:  5 HITs <BUY: Applied Genetic Technologies (AGTC +$0.63), bluebird bio (BLUE +$0.82), CRISPR Therapeutics (CRSP +$2.89), Editas Medicine (EDIT +$1.69), Pluristem (PSTI +$0.08)> and 2 MISS < SELL: Biostage (BSTG +$0.02 with 425 shares), Adverum Biotechnologies (ADVM -0.02), >  

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Monday opened positive at 24/9, 1 flat and 1 acquired, stayed positive at the mid-day to 23/11 and 1 acquired, closing positive at 25/9 and 1 acquired;

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Ultragenyx (RARE) to name 5 of the 25 inclining of the 35 covered

Hammered in today’s market:

  • Fate Therapeutics (FATE), BioLife Solutions (BLFS), AxoGen (AXGN), uniQure NV (QURE), Chinook Therapeutics (KDNY) to name 5 of the 9 declining of the 35 covered

 

Key metrics:

  • Sector volume was LOW with 0 of the 25-upside having higher than the 3-month average volume with the volume of 0 of 9-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the 25-upside were +0.55% (MDXG) to +12.02% (AGTC) while the 9-downside ranges from -0.11% (SLDB) to -3.23% (CLBS);

 

Monday’s (10 of 25) incline

  • Alnylam Pharmaceuticals (ALNY +$3.92);
  • CRISPR Therapeutics (CRSP +$2.99);
  • Intellia therapeutics (NTLA +$2.54);
  • Ultragenyx (RARE +$2.32);
  • Global Blood Therapeutics (GBT +$1.99);
  • Cellectis SA (CLLS +$1.81);
  • Editas Medicine (EDIT +$1.69);
  • Ionis Pharmaceuticals (IONS +$1.63);
  • Regenxbio (RGNX +$1.00);
  • ReNeuron (RENE.L +$1.00);

Monday’s (9 of 9) decliners:

  • Fate Therapeutics (FATE -$1.22);
  • BioLife Solutions (BLFS -$1.16);
  • AxoGen (AXGN -$0.24);
  • uniQure NV (-$0.14);
  • Chinook Therapeutics (KDNY -$0.08);
  • Caladrius Bioscience (CLBS -$0.07);
  • Verastem (VSTM -$0.05);
  • Adverum Biotechnologies (ADVM -$0.02);
  • Solid Biosciences (SLDB -$0.01);

Closing Flat: 1 - Stemline Therapeutics (STML – acquired)

 

Sentiment and COVID-19 infections:

  • The United States has fully vaccinated about 13.5% of its adult population as of Friday, according to data from the Centers for Disease Control and Prevention.

Infection cases <Million>: never to forget …

  • Monday 29.44 M cases,
  • Monday’s death rate totaled 534,946 <Johns Hopkins University>

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed up +1.49% and XBI closed up +2.17%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -0.66 points or -3.19% at 20.03

Upside volume: low

  • Monday: 0 out of the 25-upside had higher than the 3-month average volume;

Downside volume: low

  • Monday: 0 out of the 9-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Monday’s percentage (%) of the 25-upside were +0.55% (MDXG) to +12.02% (AGTC) while the 9-downside ranges from -0.11% (SLDB) to -3.23% (CLBS);

 

March, the 3rd month of Q1/21:

Monday (3/14) closed positive with 25 advancers, 9 decliners and 1 acquired

 

The BOTTOM LINE: Sustainability is the real issue in “this” market!

Markets are scary, frightening investors – volatilities basis is pure speculation i.e., gambling.

NOT for me - I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run.

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice has been … trim and skim … if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.